[{"address1": "969 Pruitt Ave", "city": "Tyler", "state": "TX", "zip": "10523", "country": "United States", "phone": "914 233 3004", "fax": "914 376 6111", "website": "https://www.nanovibronix.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.", "fullTimeEmployees": 31, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brown CPA", "age": 68, "title": "Chief Financial Officer", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 279792, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harold  Jacob M.D.", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 10000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Doron Robert Besser M.D.", "age": 55, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rita  Silberberg", "age": 49, "title": "Executive VP of Finance, Chief Accounting Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsey  Harrison", "title": "Vice President of Sales", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.31, "open": 4.1, "dayLow": 4.01, "dayHigh": 4.25, "regularMarketPreviousClose": 4.31, "regularMarketOpen": 4.1, "regularMarketDayLow": 4.01, "regularMarketDayHigh": 4.25, "payoutRatio": 0.0, "beta": 2.059, "forwardPE": -4.962963, "volume": 32684, "regularMarketVolume": 32684, "averageVolume": 78741, "averageVolume10days": 21657, "averageDailyVolume10Day": 21657, "bid": 3.06, "ask": 5.24, "bidSize": 200, "askSize": 200, "marketCap": 4374532, "fiftyTwoWeekLow": 2.09, "fiftyTwoWeekHigh": 162.5, "allTimeHigh": 18699.998, "allTimeLow": 2.09, "priceToSalesTrailing12Months": 1.6292484, "fiftyDayAverage": 4.18801, "twoHundredDayAverage": 14.948912, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 681521, "profitMargins": -2.51918, "floatShares": 1088143, "sharesOutstanding": 1088192, "sharesShort": 22848, "sharesShortPriorMonth": 43250, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.021, "heldPercentInsiders": 0.0076099997, "heldPercentInstitutions": 0.00521, "shortRatio": 0.83, "shortPercentOfFloat": 0.021, "impliedSharesOutstanding": 1088192, "bookValue": 41.998, "priceToBook": 0.09571884, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -4583000, "trailingEps": -51.81, "forwardEps": -0.81, "lastSplitFactor": "0.1:1", "lastSplitDate": 1754956800, "enterpriseToRevenue": 0.254, "enterpriseToEbitda": -0.077, "52WeekChange": -0.9681818, "SandP52WeekChange": 0.14272952, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NAOV", "underlyingSymbol": "NAOV", "shortName": "NanoVibronix, Inc.", "longName": "ENvue Medical, Inc.", "firstTradeDateEpochUtc": 1432819800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a3b94496-9e5e-3ad1-b8ab-caed8e123bbd", "messageBoardId": "finmb_27619235", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.02, "recommendationKey": "none", "totalCash": 6950000, "totalCashPerShare": 6.387, "ebitda": -8806000, "totalDebt": 3170000, "quickRatio": 0.619, "currentRatio": 0.86, "totalRevenue": 2685000, "debtToEquity": 7.465, "revenuePerShare": 15.193, "returnOnAssets": -0.19989, "returnOnEquity": -0.30512, "grossProfits": 806000, "freeCashflow": 662000, "operatingCashflow": -7244000, "revenueGrowth": 0.92, "grossMargins": 0.30019, "ebitdaMargins": 0.0, "operatingMargins": -3.11219, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]